trial

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

NCTId NCT01955564
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 54 (actual)
Sponsored by Newron Pharmaceuticals SPA
Primary completion 2014-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
54 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2013-06
Primary completion
2014-09
Eligibility
MALE · 18 Years · 45 Years

Interventions & indications

Drugs
Evenamide

Sponsors

Newron Pharmaceuticals SPALead Sponsor

Investigators

2
Mark Leibowitz, MDPrincipal Investigator
Ravi Anand, MDStudy Director

Sites

1 total
Long Beach, United States

Facts & assertions

4 sourced
Enrollment
54
Phase
PHASE1
Primary Completion Date
2014-09
Status
COMPLETED
relationships
The graph out of here
drug
Evenamide
drug
lead_sponsor
Newron Pharmaceuticals SPA
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Mark Leibowitz, MD
person
Ravi Anand, MD
person